



DLBCL

Prof. Anton Hagenbeek | ASH 2016 | Obinutuzumab or rituximab plus CHOP in first-line DLBCL patients: results of the PHASE 3 GOYA trial (Abstract 470)

 **Anne Villeneuve** | Dec 16, 2016

© 2018 Scientific Education Support Ltd. This PDF is provided for personal use only. For wider or commercial use, please seek permission from secretariat@scientificeducationsupport.com and attribute the source as: <<http://www.lymphomahub.com/medical-information/ash-2016-obinutuzumab-or-rituximab-plus-chop-in-first-line-dlbcl-patients-results-of-the-phase-3-goya-trial-abstract-470>>